Does Aranesp Treat Anemia?
Yes, Aranesp (darbepoetin alfa) treats anemia in patients with chronic kidney disease, including those on dialysis and not on dialysis. It stimulates red blood cell production by mimicking erythropoietin, a hormone kidneys produce to combat low hemoglobin levels.[1][2]
How Does Aranesp Work for Anemia?
Aranesp binds to erythropoietin receptors on bone marrow cells, prompting them to make more red blood cells. This raises hemoglobin and reduces the need for blood transfusions in kidney-related anemia. It's given by injection, typically weekly or every other week.[1][3]
What Types of Anemia Does It Target?
Aranesp is FDA-approved for anemia from chronic kidney disease. It's also used for chemotherapy-induced anemia in cancer patients when hemoglobin is low.[1][2] It does not treat other anemias like those from iron deficiency or vitamin shortages without addressing the root cause.
Common Side Effects Patients Report
Patients often experience high blood pressure, injection-site pain, or blood clots. Serious risks include stroke, heart attack, or tumor growth in cancer patients. Doctors monitor hemoglobin closely to avoid levels over 11 g/dL.[1][3]
How Does Aranesp Compare to Epogen or Procrit?
Aranesp lasts longer than Epogen (epoetin alfa) or Procrit, allowing less frequent dosing—every 1-2 weeks versus 2-3 times weekly. All are erythropoiesis-stimulating agents (ESAs) with similar efficacy but different half-lives.[2][4]
Who Makes Aranesp and When Do Patents Expire?
Amgen manufactures Aranesp. Key U.S. patents expired around 2019-2022, enabling biosimilars like those from Pfizer and Fresenius. Check DrugPatentWatch.com for exact expiry dates and litigation updates.[5]
[1] FDA Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/103951s5255lbl.pdf
[2] Aranesp Official Site: https://www.aranesp.com
[3] Mayo Clinic: https://www.mayoclinic.org/drugs-supplements/darbepoetin-alfa-subcutaneous-route-intravenous-route/description/drg-20068072
[4] Medscape Comparison: https://reference.medscape.com/drug/aranesp-epogen-procrit-darbepoetin-epoetin-alfa-342861
[5] DrugPatentWatch.com: https://www.drugpatentwatch.com/p/tradename/ARANESP